Hims vs Mochi Health: Two GLP-1 Business Models Compared

This article is part of the PlexusDx Education Hub, a library of evidence-based guidance on GLP-1 therapies, weight-management protocols, and the genetic factors that shape metabolic care. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Hims, Mochi Health, or their parent companies, and no affiliate links or paid placements appear on this page.

Search "Hims vs Mochi Health" and you are really comparing two business models more than two medications. Hims runs as a direct subscription-telehealth service; Mochi Health layers insurance-support into its telehealth. This overview walks through how each is assembled, where the two diverge, and the genetic factor neither program looks at. As of April 2026 the telehealth GLP-1 category holds dozens of entrants, so treat this as a structural snapshot of the two brands named in the query rather than a ranking.

Hims: the subscription-telehealth model

Hims, part of Hims & Hers Health, is built around a flat subscription. A member completes a virtual intake, a licensed provider reviews it, and, when appropriate, a prescription follows, either for an FDA-approved branded GLP-1 or for compounded semaglutide or tirzepatide dispensed through a licensed compounding pharmacy. Current program details live on the Hims website.

Mochi Health: the insurance-support model

Mochi Health positions itself around telehealth paired with insurance navigation, so the member experience can bend toward helping you use existing coverage rather than paying entirely out of pocket. Exactly which medications, tiers, and fees apply shifts over time; the Mochi Health website is the authoritative source on the day you read it.

Where the two models actually diverge

The clearest split is financial architecture. A subscription-first service tends to quote one predictable monthly figure; an insurance-support service introduces variables like plan design, prior authorization, and pharmacy benefits that can move your real cost up or down. Neither approach is inherently superior; they simply suit different situations, coverage statuses, and tolerances for administrative back-and-forth.

The pharmacology both models share

Whatever the storefront, the medicine is the same class. GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, plus the GIP/GLP-1 dual agonist tirzepatide, act on appetite signaling, satiety, and gastric emptying. Trial programs including STEP (semaglutide, NEJM 2021) and SURMOUNT (tirzepatide, NEJM 2022) established the class; effect size tracks the compound and dose, not the brand handing it to you.

The genetic layer neither model maps

What no subscription tier or insurance workflow captures is your upstream metabolic biology. A variant in FTO, the fat-mass and obesity-associated gene, along with GLP1R (the receptor every GLP-1 drug targets) and MC4R (central to satiety), describes the terrain a clinician prescribes into. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across that terrain. It does not predict how you will respond to any specific medication; it maps the biology the medication is entering.

How PlexusDx approaches the same category

PlexusDx dispenses semaglutide and tirzepatide through its Weight Management Protocols, offered as Semaglutide Injection at $189/month, Semaglutide Oral, Tirzepatide Injection at $289/month, and Tirzepatide Oral. The difference is sequence: the Precision Peptide Genetic Test comes first, so you begin an informed conversation with a provider instead of a blind one.

Not affiliated: PlexusDx has no commercial relationship with Hims, Mochi Health, or any brand named in this comparison.

Keep reading on PlexusDx: GLP-1 Receptor Agonist, GLP-1 Drugs, GLP-1 Hormone, What Is GLP-1.

Editorial note: this comparison is educational. PlexusDx sells semaglutide and tirzepatide through its own Weight Management Protocols and is not affiliated with the companies reviewed. The Precision Peptide Genetic Test reports how your genes influence peptide-related pathways and does not predict response to any medication. Talk with a qualified healthcare provider before starting a protocol.

Frequently Asked Questions

Does Mochi Health work with insurance while Hims does not?

Mochi Health markets insurance navigation as part of its model, whereas Hims is generally a cash-subscription service. Coverage still depends on your individual plan, the specific medication, and prior-authorization rules, so confirm the current terms directly with each company before assuming what your out-of-pocket cost will be.

Which model is cheaper, Hims or Mochi Health?

There is no universal answer. A subscription can be cheaper when you have no relevant coverage, while an insurance-support path can win when your plan pays part of the cost. Because pricing shifts and depends on your plan, compare current figures on each brand site rather than relying on a fixed number here.

Do the two programs prescribe different medications?

Both operate within the same GLP-1 drug class and may offer semaglutide or tirzepatide depending on eligibility and supply. The pharmacology is identical across legitimate programs; what genuinely differs is the business model, the dispensing pathway, and the provider oversight wrapped around the prescription.

Where does genetic testing fit alongside either service?

Genetic testing sits upstream of both. The Precision Peptide Genetic Test maps variants like FTO, GLP1R, and MC4R that describe your baseline metabolic biology. That context applies no matter which telehealth program eventually writes the prescription, which is why it complements rather than replaces either service.

This article belongs to the PlexusDx Education Hub. Browse all Peptides & GLP-1 education